Explore how oncologists battle information overload, navigate conflicting trial data, and weigh AI tools while keeping ...

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk ...

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...

Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...

Daniel Ermann, MD, discusses treatment considerations with newly diagnosed older/elderly patients with chronic lymphocytic ...

Daniel Ermann, MD, highlights 6.5-year follow-up data for zanubrutinib from the phase 3 SEQUOIA trial, which compared the BTK ...

Daniel Ermann, MD, discusses a retrospective study he presented at the 2026 ASCO Annual Meeting that compared real-world ...

Daniel Ermann, MD, discusses his approach to treatment sequencing in patients with chronic lymphocytic leukemia who aged 80 ...

Daniel Ermann, MD, discusses what long-term clinical trial and real-world data have shown about the benefits and durability ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...